FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907492778> ?p ?o ?g. }

• W2907492778 abstract "Background and Objective: Development of drugs such as tyrosine kinase inhibitors (TKIs), immunomodulatory drugs (IMiDs), or proteasome inhibitors (PIs) have improved survival of hematologic malignancies including chronic myeloid leukemia (CML) and multiple myeloma (MM). However, some patients eventually relapse by discontinuation of the drugs or acquiring resistance to the drugs. Thus, it is crucial to develop novel therapy for cure of these malignancies. CML and MM are considered to be relatively immunogenic diseases among hematologic malignancies and immunotherapy might be useful. Since CML cells or MM cells have few somatic mutations which result in amino acid changes and give rise to neoantigens, checkpoint inhibitors alone may not be sufficient to evoke effective immunity against these cells. Instead, overexpressed antigen may be an attractive therapeutic target. We have identified CXorf48 as a highly expressed antigen in several hematologic malignancies including CML and MM. In this study, we investigated whether CXorf48 could serve as a therapeutic target for CML and MM. Methods and Results: High expression of CXorf48 gene in CML cells and MM cells was confirmed by quantitative PCR and also patients’ gene data obtained from a public repository. In contrast, BMMNCs cells or PBMNCs from healthy donor did not express CXorf48. We induced CXorf48-specific cytotoxic T lymphocytes (CTLs) by stimulating lymphocytes from healthy donors with HLA-A24:02-restricted CXorf48-derived epitope peptide. ELISpot assay, cytotoxic assay and CD107a mobilization assay showed that these CTLs preferentially recognized CML cells and MM cells. Moreover, we could detect CXorf48-specific CTL in peripheral blood of CML patients who remained in complete molecular remission after cessation of TKIs. Conclusion: Our data suggest that CXorf48 is a novel therapeutic target of CTLs in CML or MM. Immunotherapy against this antigen, such as vaccination therapy or adoptive T-cell therapy after conventional therapies might be an attractive therapeutic strategy for cure of CML and MM. Citation Format: Maiko Matsushita, Shinya Yokoe, Koji Ozawa, Saori Kanchi, Daiju Ichikawa, Eri Matsuki, Takehiko Mori, Shinichiro Okamoto, Yutaka Hattori. Evaluation of novel immune target in hematologic malignancies [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2017 Oct 1-4; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2018;6(9 Suppl):Abstract nr A82." @default.
• W2907492778 created "2019-01-11" @default.
• W2907492778 creator A5008387148 @default.
• W2907492778 creator A5021956519 @default.
• W2907492778 creator A5029913678 @default.
• W2907492778 creator A5038240936 @default.
• W2907492778 creator A5044647383 @default.
• W2907492778 creator A5051983260 @default.
• W2907492778 creator A5056260888 @default.
• W2907492778 creator A5067791595 @default.
• W2907492778 creator A5081878134 @default.
• W2907492778 date "2018-09-01" @default.
• W2907492778 modified "2023-09-28" @default.
• W2907492778 title "Abstract A82: Evaluation of novel immune target in hematologic malignancies" @default.
• W2907492778 doi "https://doi.org/10.1158/2326-6074.tumimm17-a82" @default.
• W2907492778 hasPublicationYear "2018" @default.
• W2907492778 type Work @default.
• W2907492778 sameAs 2907492778 @default.
• W2907492778 citedByCount "0" @default.
• W2907492778 crossrefType "proceedings-article" @default.
• W2907492778 hasAuthorship W2907492778A5008387148 @default.
• W2907492778 hasAuthorship W2907492778A5021956519 @default.
• W2907492778 hasAuthorship W2907492778A5029913678 @default.
• W2907492778 hasAuthorship W2907492778A5038240936 @default.
• W2907492778 hasAuthorship W2907492778A5044647383 @default.
• W2907492778 hasAuthorship W2907492778A5051983260 @default.
• W2907492778 hasAuthorship W2907492778A5056260888 @default.
• W2907492778 hasAuthorship W2907492778A5067791595 @default.
• W2907492778 hasAuthorship W2907492778A5081878134 @default.
• W2907492778 hasConcept C147483822 @default.
• W2907492778 hasConcept C154317977 @default.
• W2907492778 hasConcept C167672396 @default.
• W2907492778 hasConcept C202751555 @default.
• W2907492778 hasConcept C203014093 @default.
• W2907492778 hasConcept C2777701055 @default.
• W2907492778 hasConcept C2779053233 @default.
• W2907492778 hasConcept C502942594 @default.
• W2907492778 hasConcept C55493867 @default.
• W2907492778 hasConcept C71924100 @default.
• W2907492778 hasConcept C86803240 @default.
• W2907492778 hasConcept C8891405 @default.
• W2907492778 hasConceptScore W2907492778C147483822 @default.
• W2907492778 hasConceptScore W2907492778C154317977 @default.
• W2907492778 hasConceptScore W2907492778C167672396 @default.
• W2907492778 hasConceptScore W2907492778C202751555 @default.
• W2907492778 hasConceptScore W2907492778C203014093 @default.
• W2907492778 hasConceptScore W2907492778C2777701055 @default.
• W2907492778 hasConceptScore W2907492778C2779053233 @default.
• W2907492778 hasConceptScore W2907492778C502942594 @default.
• W2907492778 hasConceptScore W2907492778C55493867 @default.
• W2907492778 hasConceptScore W2907492778C71924100 @default.
• W2907492778 hasConceptScore W2907492778C86803240 @default.
• W2907492778 hasConceptScore W2907492778C8891405 @default.
• W2907492778 hasLocation W29074927781 @default.
• W2907492778 hasOpenAccess W2907492778 @default.
• W2907492778 hasPrimaryLocation W29074927781 @default.
• W2907492778 hasRelatedWork W1794808949 @default.
• W2907492778 hasRelatedWork W1825698198 @default.
• W2907492778 hasRelatedWork W1970289093 @default.
• W2907492778 hasRelatedWork W1982131842 @default.
• W2907492778 hasRelatedWork W2008949385 @default.
• W2907492778 hasRelatedWork W2055759108 @default.
• W2907492778 hasRelatedWork W2166919567 @default.
• W2907492778 hasRelatedWork W2220102944 @default.
• W2907492778 hasRelatedWork W2242587286 @default.
• W2907492778 hasRelatedWork W2374990112 @default.
• W2907492778 isParatext "false" @default.
• W2907492778 isRetracted "false" @default.
• W2907492778 magId "2907492778" @default.
• W2907492778 workType "article" @default.